BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TauRx Therapeutics Release: First UK Patients Enroll in Phase 3 Clinical Trials of LMTX™ for Alzheimer's Disease


5/23/2013 10:05:27 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Aberdeen, United Kingdom, 22 May 2013 – Coinciding with Dementia Awareness Week in the UK, TauRx Therapeutics Ltd announced that the first of more than 100 UK patients have enrolled in the global Phase 3 clinical trials of LMTX™ for mild to moderate Alzheimer’s disease.

“The initiation of our clinical studies in the UK marks an important step forward in our quest to find a disease-modifying agent that can help slow or halt the progression of Alzheimer’s disease,” said Prof. Claude Wischik, Executive Chairman and Co-Founder of TauRx Therapeutics. “Unlike cancer, for Alzheimer’s there are no ‘Alzheimer’s survivors’, so a medicine that can keep people functioning and at home longer is essential.”

The Phase 3 trials of the tau aggregation inhibitor target ‘tau tangles’ in the brain, and could provide the first definitive data on a tau-based treatment that dissolves the tangles and slows or halts Alzheimer’s disease.

Prof. Wischik added, “It is hoped that this study will shed new light on our understanding of how tau tangles form, their role in dementia, and ultimately how to stop them from spreading in the brain. LMTX™ could also provide a basis for preventive treatment of Alzheimer’s before any symptoms appear.”

The two large, Phase 3 studies will involve over 1,500 patients in more than 20 countries, with about 16 medical centres participating in the UK. These studies culminate three decades of research by Professor Claude Wischik and colleagues at TauRx Therapeutics, a spin-out company from the University of Aberdeen, Scotland established 11 years ago. According to the UK’s Alzheimer’s Society, there are currently 800,000 people in the UK living with dementia and this is expected to grow to over a million people by 2021. Currently no treatments are available to stop or reverse this devastating disease, which is now one of the leading causes of death in the UK.

For more information and updates about the Phase 3 clinical trials in Alzheimer’s disease or TauRx Therapeutics, patients and carers can visit www.alzheimersglobalstudies.net.

About TauRx Therapeutics:

TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company’s tau aggregation inhibitor, LMTX™, is currently in global Phase 3 clinical trials for Alzheimer’s and Frontotemporal Dementia (FTD). LMTX™ targets aggregates of abnormal fibres of tau protein that form inside nerve cells in the brain, giving rise to tangles. TauRx’s primary research facilities are in Aberdeen, Scotland.

For press enquiries please contact:

Sylvie Berrebi +44 (0)7795 197271

Elizabeth Puller +44 (0)208 834 1447

Email: press@taurx.com

Website: www.taurx.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES